Novartis reports positive results from Phase III study with pasireotide

Novartis has reported positive results from Phase III study which showed that Pasireotide (SOM230) long-acting release (LAR) was effective at inducing full biochemical control compared to Sandostatin…
Read the full story: PBR - Clinical Trials News